07:00 , Oct 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Hyperlipidemia Fatty acid desaturase 3 (FADS3) A genomics study suggests that antagonizing FADS3 could help treat hyperlipidemia. A genomewide analysis showed that carriers of...